JPND research
EU Joint Programme – Neurodegenerative Disease Research

IMBI

Framework for Innovative Multi-tracer molecular Brain Imaging (IMBI) to enable multi-centre trials and image evaluation in (early) neurodegenerative diseases

The main objective of the IMBI Working Group is to establish a structured framework for the use of positron emission tomography (PET) imaging in the diagnosis and monitoring of degenerative brain diseases such as Alzheimer's, Parkinson's and Huntington's disease, among others. The final goal is to set up a roadmap of best validated practices at the various phases in the application of this imaging technique to detect and discriminate between different types and different phases (early, late) of degenerative brain disorders and to evaluate disease-modifying therapies. This will include the development of (i) highly specific and/or innovative imaging tracers capable of very sensitively detecting specific hallmarks of the underlying diseases, (ii) protocols for harmonised and standardised image acquisition, processing and analysis and (iii) protocols for clinical trials either using single or multiple imaging tracers or performed in single or multiple centres. The recommendations made by this Working Group will lead to improved personalised medicine, with high accuracy in early disease detection, as well as in the implementation of clinical trials and non-invasive neuroimaging follow-up of disease-specific therapies at different disease stages.

Coordinator: Andreas H. Jacobs
E: ahjacobs@uni-muenster.de
T: +49 251 83-49300



Working Group Members:

COORDINATOR I ANDREAS JACOBS

CO-COORDINATOR I DANIELA PERANI

K. Van Laere, University Hospital Leuven, KU Leuven, Belgium

D. Brooks, Aarhus University, Denmark
M.M. Herth, University of Copenhagen, Denmark
G.M. Knudsen, Rigshospitalet, Region Hovedstaden, Denmark

F. Lopez Picon, Turku PET Centre, Hospital District of Southwest Finland, Finland
J. Rinne, Turku University Hospital, Hospital District of Southwest Finland, Finland

M. Bottlaender, Service Hospitalier Frédéric Joliot, CEA, France
S. Chalon, Inserm-U930, University of Tours, France
B. Kuhnast, Service Hospitalier Frédéric Joliot, CEA, France
M.J. Santiago-Ribeiro, CHU, University of Tours, France
J. Vercouillie, CERRP Tours, University of Tours, France
A. Winkeler, Service Hospitalier Frédéric Joliot, CEA, France

A.H. Jacobs, European Institute for Molecular Imaging, University of Münster, Germany

R.M. Moresco, University of Milan Bicocca, Italy
S. Pappata, Institute of Biostructure and Bioimaging (IBB), National Research Council (CNR), Naples, Italy
D. Perani, San Raffaele Hospital, Vita-Salute San Raffaele University, Italy

R. Boellaard, Academisch Ziekenhuis Groningen, the Netherlands
A.A. Lammertsma, VU University Medical Center, the Netherlands
A.D. Windhorst, VU University Medical Center, the Netherlands

Ch. Halldin, Karolinska Institutet, Sweden
O. Hansson, Lund University, Sweden
A. Nordberg, Karolinska University Hospital Huddinge, Sweden
E. Rodriguez-Vieitez, Karolinska Institutet, Sweden
A. Varrone, Karolinska Institutet, Sweden

M.A. Carroll, University of Newcastle, UK
P. Edison, Imperial College London, UK
A. Gee, King's College London, UK
A. Gerhard, University of Manchester, UK
K. Herholz, University of Manchester, UK
R. Hinz, University of Manchester, UK
F.E. Turkheimer, King's College London, UK